Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.
Here's a review of the two company announcements made during the month:
Given the upbeat news items, I'm once again left scratching my head as to why shares fell so much last month.
Source: Fool.com
Amgen Inc. Stock
€309.95
0.490%
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
On the other hand, the target price of 304 € is below the current price of 309.95 € for Amgen Inc., so the potential is actually -1.92%.
